Immunome, Inc.

IMNM

NASDAQ

Healthcare

Biotechnology

Bothell, PA, US131 employeesimmunome.com

$21.86

-0.59(-2.63%)

Mkt Cap $1.9B

$5.56

$26.97

52-Week Range

At A Glance

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.

Revenue is primarily driven by Single Reportable Segment (100%).

Most recently: of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A (2026-03-03).

$1.9B

Market Cap

$7M

Revenue

-$214M

Net Income

Employees131

Fundamentals

How The Business Makes Money

Revenue by Segment

Single Reportable Segment100%($16M)

Activity

What Changed Recently

Financial Results

Mar 2, 2026

of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A

Peer Companies

Company	Price	Change	Market Cap	P/E
VERAVera Therapeutics, Inc.	$40.82	+0.79%	$2.9B	-8.7
SYRESpyre Therapeutics, Inc.	$47.67	-2.52%	$2.9B	-95.3
CLDXCelldex Therapeutics, Inc...	$31.00	-0.85%	$2.1B	-8.2
PHVSPharvaris N.V.	$28.50	-3.21%	$1.9B	-8.3
NTLAIntellia Therapeutics, In...	$13.13	-1.09%	$1.6B	-3.4
MAZEMaze Therapeutics, Inc.	$28.82	-0.77%	$1.4B	-17.8
ABCLAbCellera Biologics Inc.	$3.54	+0.71%	$1.1B	-6.9
BHVNBiohaven Ltd.	$9.78	+1.66%	$1.0B	-1.4

Analyst View

Company Profile

CIK0001472012

ISINUS45257U1088

CUSIP45257U108

Phone610 321 3700

Address665 Stockton Drive, Bothell, PA, 19341, US

SEC EDGAR